Management of acute ischaemic stroke in the elderly: Tolerability of thrombolytics

Drugs

Volumn 61, Issue 10, 2001, Pages 1439-1453

  Tanne, David ^a   Turgeman, Deborah ^a   Adler, Yehuda ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; FIBRINOLYTIC AGENT; STREPTOKINASE;

ACUTE HEART INFARCTION; DRUG TOLERANCE; FIBRINOLYTIC THERAPY; HUMAN; REVIEW; STROKE;

AGE FACTORS; AGED; AGED, 80 AND OVER; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; EMERGENCY MEDICINE; FIBRINOLYTIC AGENTS; HUMANS; MYOCARDIAL INFARCTION; PATIENT SELECTION; RISK FACTORS; TRIAGE;

EID: 0034874983     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200161100-00007     Document Type: Review

References (97)

1. Epidemiology of stroke
2. A prospective study of acute cerebrovascular disease in the community: The Oxfordshire Community Stroke Project 1981-86. 1. Methodology, demography and incident cases of first-ever stroke
3. Probability of stroke: A risk profile from the Framingham Study
4. Risk profile and prediction of long-term ischemic stroke mortality: A 21-year follow-up in the Israeli Ischemic Heart Disease (IIHD) Project
5. Incidence and occurrence of total (first-ever and recurrent) stroke
6. Stroke incidence, prevalence, and survival: Secular trends in Rochester, Minnesota, through 1989
7. The frequency, causes and timing of death within 30 days of a first stroke: The Oxfordshire Community Stroke Project
8. Stroke in the elderly aged 75 years and above
9. Strokes in the elderly - Higher acute and 3-month mortality - An explanation
10. The influence of age on stroke outcome. The Copenhagen Stroke Study
11. Comparison of stroke features and disability in daily life in patients with ischemic stroke aged 55 to 70 and 71 to 85 years
12. Stroke severity in atrial fibrillation. The Framingham Study
13. Atrial fibrillation: A major contributor to stroke in the elderly. The Framingham Study
14. Total quality improvement method for reduction of delays between emergency department admission and treatment of acute ischemic stroke
15. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience
16. Patients' awareness of stroke signs, symptoms, and risk factors
17. Public perception of stroke warning signs and knowledge of potential risk factors
18. Identifying stroke in the field. Prospective validation of the Los Angeles prehospital stroke screen (LAPSS)
19. Cincinnati Prehospital Stroke Scale: Reproducibility and validity
20. Acute stroke: Usefulness of early CT findings before thrombolytic therapy
21. Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy
22. Can stroke physicians and neuroradiologists identify signs of early cerebral infarction on CT?
23. Validity and reliability of a quantitative computed tomography score in predicting outcome of hypcracute stroke before thrombolytic therapy
24. Alternative strategies for stroke care: A prospective randomised controlled trial
25. Organization of stroke care: Education, stroke units and rehabilitation. European Stroke Initiative (EUSI)
26. Organised inpatient (stroke unit) care for stroke
27. Where and how should elderly stroke patients be treated? A randomized trial
28. Effect of acute stroke unit care integrated with care continuum versus conventional treatment: A randomized 1-year study of elderly patients: The Goteborg 70+ stroke study
29. Treatment and secondary prevention of stroke: Evidence, costs, and effects on individuals and populations
30. Recommendations for the establishment of primary stroke centers
31. Clinical and instrumental evaluation of patients with ischemic stroke within the first six hours
32. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke
33. Thresholds in cerebral ischemia - The ischemic penumbra
34. Tissue plasminogen activator reduces neurological damage after cerebral embolism
35. Reduction of infarct volume and mortality by thrombolysis in a rat embolic stroke model
36. The clot thickens-thrombolysis and combination therapies
37. Randomised controlled trial of streptokinase, aspirin, and combination in treatment of acute ischaemic stroke
38. Thrombolytic therapy with streptokinase in acute ischemic stroke
39. Streptokinase for acute ischemic stroke with relationship to time of administration: Australian Streptokinase (ASK) Trial Study Group
40. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS)
41. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II)
42. Tissue plasminogen activator for acute ischemic stroke
43. Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS Study: A randomized controlled trial. Alteplase Thrombolysis for Acute Noninterventional Therapy in Ischemic Stroke
44. Intra-arterial prourokinase for acute ischemic stroke. The PROACT II study: A randomized controlled trial. Prolyse in Acute Cerebral Thromboembolism
45. Initial clinical experience with IV tissue plasminogen activator for acute ischemic stroke: A multicenter survey
46. Should use of t-PA for ischemic stroke be restricted to specialized stroke centers
47. Early intravenous thrombolysis for acute ischemic stroke in a community-based approach
48. Intravenous TPA for ischemic stroke patients: Houston experience 1996-2000
49. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study
50. Intravenous Alteplase for stroke: The Canadian experience
51. Streptokinase in acute ischemic stroke: An individual patient data meta-analysis: The Thrombolysis in Acute Stroke Pooling Project
52. Treatment of acute ischemic stroke
53. Antithrombotic and thrombolytic therapy for ischemic stroke
54. Effects of tissue plasminogen activator for acute ischemic stroke at one year
55. Early stroke treatment associated with better outcome: The NINDS rt-PA stroke study
56. Generalized efficacy of t-PA for acute stroke. Subgroup analysis of the NINDS t-PA Stroke Trial
57. A systems approach to immediate evaluation and management of hyperacute stroke. Experience at eight centers and implications for community practice and patient care
58. Practice advisory: Thrombolytic therapy for acute ischemic stroke - Summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology
59. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke. A statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association
60. European Stroke Initiative recommendations for stroke management, European Stroke Council, European Neurological Society and European Federation of Neurological Societies
61. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke
62. Thrombolysis in acute ischemic stroke: Controlled trials and clinical experience
63. One-year follow-up in acute stroke patients treated with rtPA in clinical routine
64. Effectiveness of t-PA in acute ischemic stroke: Outcome relates to appropriateness
65. Protocol violations in community-based rTPA stroke treatment are associated with symptomatic intracerebral hemorrhage
66. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke
67. Prediction of intracerebral hemorrhage after intravenous rt-PA therapy for acute ischemic stroke in clinical practice: The multicenter acute stroke survey
68. Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke
69. Anaphylactoid reactions and angioedema during alteplase treatment of acute ischemic stroke
70. Orolingual angioneurotic edema following therapy of acute ischemic stroke with alteplase
71. Evidence of anaphylaxy after alteplase infusion
72. Intra-arterial thrombolysis in acute stroke
73. Combined intravenous and intra-arterial r-TPA versus intra-arterial therapy of acute ischemic stroke. Emergency Management of Stroke (EMS) bridging trial
74. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke
75. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study
76. Risk factors for severe hemorrhagic transformation in ischemic stroke patients treated with recombinant tissue plasminogen activator: A secondary analysis of the European-Australasian Acute Stroke Study (ECASS II)
77. Intravenous tissue plasminogen activator for acute ischemic stroke in patients aged 80 years and older: The tPA stroke survey experience
78. Intravenous tissue plasminogen activator for acute ischemic stroke in patients 80 years old: The London, Canada experience
79. Cerebral amyloid angiopathy: An overview
80. Diagnosis of cerebral amyloid angiopathy. Sensitivity and specificity of cortical biopsy
81. Clinical features and pathogenesis of intracerebral hemorrhage after rt-PA and heparin therapy for acute myocardial infarction: The Thrombolysis in Myocardial Infarction (TIMI) II Pilot and Randomized Clinical Trial combined experience
82. Risk factors and leukoaraiosis in stroke patients
83. Thrombolysis for acute ischaemic stroke
84. White matter changes in stroke patients. Relationship with stroke subtype and outcome
85. Major bleeding during anticoagulation after cerebral ischemia: Patterns and risk factors. Stroke Prevention in Reversible Ischemia Trial (SPIRIT)
86. Liver blood flow as a major determinant of the clearance of recombinant human tissue-type plasminogen activator
87. Clearance of plasminogen activator- a major determinant of plasma concentration: Therapeutic and diagnostic implications
88. Indications for fibrinolytic therapy in suspected acute myocardial infarction: Collaborative overview of early mortality and major morbidity results from all randomized trials of more than 1000 patients
89. Thrombolytic therapy in the elderly. Pharmacoeconomic considerations
90. Utilisation of thrombolytic therapy in older patients with myocardial infarction
91. Lack of benefit for intravenous thrombolysis in patients with myocardial infarction who are older than 75 years
92. Intracranial hemorrhage associated with thrombolytic therapy for elderly patients with acute myocardial infarction: Results from the Cooperative Cardiovascular Project
93. Risk for intracranial hemorrhage after tissue plasminogen activator treatment for acute myocardial infarction. Participants in the National Registry of Myocardial Infarction 2
94. Individual risk assessment for intracranial haemorrhage during thrombolytic therapy
95. Primary coronary angioplasty vs thrombolysis for the management of acute myocardial infarction in elderly patients
96. Thrombolytic therapy for patients with myocardial infarction who are older than 75 years. Do the risks outweigh the benefits?
97. Age related outcome in acute myocardial infarction. Elderly people benefit from thrombolysis and should be included in trials